Novel Coronavirus is reported to cause COVID-19, recently. It's known that this virus uses ACE (angiotensin converting enzyme) 2 receptors to enter human cells and also blocks the activity of ACE 2. Upon these data the investigators hypothesize that, mortal hyper-inflammation state which is shown in COVID-19 cases, can be a result of angiotensin peptide (1-7) deficiency. Therefore, the aim of this study is to evaluate the possible effect of angiotensin peptide (1-7) supplementation on treatment of COVID-19 cases.
Novel Coronavirus is reported to cause COVID-19, recently. It's known that this virus uses
ACE (angiotensin converting enzyme) 2 receptors to enter human cells and also blocks the
activity of ACE 2. Upon these data the investigators hypothesize that, mortal
hyper-inflammation state which is shown in COVID-19 cases, can be a result of angiotensin
peptide (1-7) deficiency. Therefore, the aim of this study is to evaluate the possible effect
of plasma derived angiotensin peptide (1-7) supplementation on treatment of COVID-19 cases.
Biological: Biological/Vaccine: Angiotensin peptide (1-7) derived plasma
angiotensin peptide (1-7) derived plasma will be given to COVID-19 positive participants
Inclusion Criteria:
- accepted to participate with an informed consent
- proven positive COVID-19
Exclusion Criteria:
- declined to participate
- genetic/chromosomal abnormalities
- any kind of history of previous adverse events with transfusion
- diagnosis of immune deficiency
Kanuni Sultan Suleyman Training and Research Hospital
Istanbul, Turkey